Frost & Sullivan commends Merck Serono for its excellence in product differentiation

16-May-2013 - Germany

Merck Serono announced that based on its recent analysis of the human growth hormones (HGH) market, Frost & Sullivan recognises Merck Serono with the 2013 Europe Product Differentiation Excellence Award.

“Merck Serono is lauded for its cutting-edge drug delivery devices - easypod® and cool.click®2 – that facilitate the simple and effective administration of Saizen®, the recombinant HGH used for the treatment of endogenous growth hormone deficiency in children and adults,” noted Frost & Sullivan Healthcare Senior Research Analyst Aiswariya Chidambaram. “These devices successfully address long standing challenges related to poor patient compliance and low adherence to HGH therapy.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances